Evidence map›Paper›PMID 38110654›Full record

ArticleAdvances in therapy2024

Living with Cerebrotendinous Xanthomatosis: Patient, Caregiver, and Expert Perspectives.

Robert D Steiner, Andrea DeBarber, Austin Larson, Bobbi Blanchard, Shawn Laurie, Neel Odedara, Hollisa Rosengrant, Rana Dutta

Open access · hybridAbstract read
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Robert D SteinerUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Andrea DeBarberUniversity Shared Resources, Oregon Health and Science University, Portland, OR, USA.
Austin LarsonDepartment of Pediatrics, Section of Genetics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA.
Bobbi Blanchard, New Richmond, WI, USA.
Shawn Laurie, Mansfield, TX, USA.
Neel Odedara, New York, NY, USA.
Hollisa Rosengrant, Chicago, IL, USA.
Rana DuttaMirum Pharmaceuticals, Inc., 950 Tower Lane Suite 1050, Foster City, CA, 94404, USA. rana.dutta@mirumpharma.com.
Mansfield University · USNew York Proton Center · USOregon Health & Science University · USSpectrum Pharmaceuticals (United States) · USUniversity of Colorado Denver · USUniversity of Richmond · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, patients with cerebrotendinous xanthomatosis (CTX) and caregivers detail their experience with lifelong symptoms, diagnosis, treatment and efficacy, and ongoing disease management. One patient and four caregivers describe the challenges associated with pursuing a correct diagnosis for years before testing confirmed a CTX diagnosis. They also detail their ongoing struggles and desire for greater access to physicians with CTX knowledge and to reliable online resources to continue their education about the disease and strategies for symptom management. The expert perspective is a direct response by three CTX researchers, including physicians who are treating patients with CTX in the United States and experts whose laboratories provide genetic and biochemical testing for CTX. They respond to many of the patient and caregiver concerns, including steps that are being taken to identify CTX earlier and provide access to confirmatory diagnostic testing sooner, and suggest the best online resources for CTX-related information and access to webinars and support groups. While the expert perspective is a direct response to the patient and caregiver authors' CTX journeys, it should be beneficial to any patient with CTX or their caregivers.

Indexed as

Xanthomatosis, CerebrotendinousCaregiversCholestanetriol 26-MonooxygenaseHumansCholestanetriol 26-MonooxygenaseCDCACerebrotendinous xanthomatosisChenodeoxycholic acidCTXCYP27A1

Identifiers

PMID38110654
PMCPMC10838853
OpenAlexW4389958256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.